| Previous close | 214.20 |
| Open | 211.91 |
| Bid | 214.23 x 800 |
| Ask | 216.56 x 1100 |
| Day's range | 211.52 - 217.10 |
| 52-week range | 49.91 - 252.78 |
| Volume | 2,256,063 |
| Avg. volume | 3,004,861 |
| Market cap | 51.304B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 09 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 194.87 |
- Zacks
Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate
Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.
- Motley Fool
Why BioNTech, Moderna, and Novavax Stocks Sank This Week
Shares of BioNTech (NASDAQ: BNTX) were down 10.2% for the week, as of the market close on Thursday. Moderna (NASDAQ: MRNA) stock fell 7.5%, and Novavax (NASDAQ: NVAX) tumbled 14.2%. The decline for Novavax might be the most puzzling.
- Globe Newswire
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma
First program from BioNTech’s fully-owned mRNA cancer vaccine platform FixVac treats patients in a randomized clinical Phase 2 clinical trial Phase 2 trial is based on positive results from Phase 1 Lipo-MERIT trial that demonstrated a favorable safety profile for BNT111 as well as durable objective responses observed in patients with melanoma who had progressed following prior checkpoint blockadeTrial is enrolling a total of 120 patients at clinical trial sites in the European Union, the United
